NCT05882513View on ClinicalTrials.gov

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2030

Conditions
NSCLCNeoadjuvant Therapy
Interventions
DRUG

Serplulimab and neoadjuvant therapy

"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."

PROCEDURE

surgical resection of lung cancer

radical resection of lung cancer

OTHER

Tumour will be Collected from participant. Fate of sample is Destruction after use

Tumour sample will be collected after surgery

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER